180 related articles for article (PubMed ID: 10959605)
1. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.
Inoue A; Tsukuma H; Oshima A; Yabuuchi T; Nakao M; Matsunaga T; Kojima J; Tanaka S
J Epidemiol; 2000 Jul; 10(4):234-40. PubMed ID: 10959605
[TBL] [Abstract][Full Text] [Related]
2. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
[TBL] [Abstract][Full Text] [Related]
3. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
4. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
6. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.
Yoshida H; Tateishi R; Arakawa Y; Sata M; Fujiyama S; Nishiguchi S; Ishibashi H; Yamada G; Yokosuka O; Shiratori Y; Omata M
Gut; 2004 Mar; 53(3):425-30. PubMed ID: 14960528
[TBL] [Abstract][Full Text] [Related]
7. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study.
Ikeda K; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Murashima N; Chayama K; Kumada H
J Gastroenterol Hepatol; 2001 Apr; 16(4):406-15. PubMed ID: 11354279
[TBL] [Abstract][Full Text] [Related]
8. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
[TBL] [Abstract][Full Text] [Related]
9. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Hayashi K; Honda T
Oncology; 2001; 61(2):134-42. PubMed ID: 11528252
[TBL] [Abstract][Full Text] [Related]
10. [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].
Nishiguchi S; Kubo S; Shiomi S
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):600-4. PubMed ID: 15359868
[No Abstract] [Full Text] [Related]
11. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon.
Veldt BJ; Hansen BE; Ikeda K; Verhey E; Suzuki H; Schalm SW
Scand J Gastroenterol; 2006 Sep; 41(9):1087-94. PubMed ID: 16938723
[TBL] [Abstract][Full Text] [Related]
12. Management of chronic hepatitis C and prevention of hepatocellular carcinoma.
Chayama K
J Gastroenterol; 2002; 37 Suppl 13():69-73. PubMed ID: 12109670
[TBL] [Abstract][Full Text] [Related]
13. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.
Shiratori Y; Ito Y; Yokosuka O; Imazeki F; Nakata R; Tanaka N; Arakawa Y; Hashimoto E; Hirota K; Yoshida H; Ohashi Y; Omata M;
Ann Intern Med; 2005 Jan; 142(2):105-14. PubMed ID: 15657158
[TBL] [Abstract][Full Text] [Related]
14. Interferon therapy reduces the risk for hepatocellular carcinoma.
Brown JL
Gut; 2000 Nov; 47(5):610-1. PubMed ID: 11034573
[No Abstract] [Full Text] [Related]
15. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.
Hino K; Kitase A; Satoh Y; Fujiwara D; Yamaguchi Y; Korenaga M; Shingai Y; Konishi T; Yamashita S; Uchida K; Mori K; Hanada H; Kodama T; Nukui K; Okita K
J Viral Hepat; 2002 Sep; 9(5):370-6. PubMed ID: 12225332
[TBL] [Abstract][Full Text] [Related]
16. Long-term cohort study of chronic hepatitis C according to interferon efficacy.
Maruoka D; Imazeki F; Arai M; Kanda T; Fujiwara K; Yokosuka O
J Gastroenterol Hepatol; 2012 Feb; 27(2):291-9. PubMed ID: 21793911
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C and interferon: fewer cases of liver cancer.
Prescrire Int; 2013 Jul; 22(140):191. PubMed ID: 23951600
[TBL] [Abstract][Full Text] [Related]
18. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan.
Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T
J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762
[TBL] [Abstract][Full Text] [Related]
19. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
20. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.
Omata M; Yoshida H; Shiratori Y
Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S141-3. PubMed ID: 16234063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
